JP2009545313A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009545313A5 JP2009545313A5 JP2009522733A JP2009522733A JP2009545313A5 JP 2009545313 A5 JP2009545313 A5 JP 2009545313A5 JP 2009522733 A JP2009522733 A JP 2009522733A JP 2009522733 A JP2009522733 A JP 2009522733A JP 2009545313 A5 JP2009545313 A5 JP 2009545313A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- muscle
- sequence
- disease
- terminal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 27
- 229920001184 polypeptide Polymers 0.000 claims 23
- 102000004196 processed proteins & peptides Human genes 0.000 claims 23
- 108020001507 fusion proteins Proteins 0.000 claims 14
- 102000037865 fusion proteins Human genes 0.000 claims 14
- 150000001413 amino acids Chemical class 0.000 claims 11
- 210000004899 c-terminal region Anatomy 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 108010056852 Myostatin Proteins 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 7
- 230000001575 pathological effect Effects 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 6
- 102000004472 Myostatin Human genes 0.000 claims 5
- 201000000585 muscular atrophy Diseases 0.000 claims 4
- 229920002704 polyhistidine Polymers 0.000 claims 4
- 230000001737 promoting effect Effects 0.000 claims 4
- 206010028289 Muscle atrophy Diseases 0.000 claims 3
- 208000029549 Muscle injury Diseases 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 230000008468 bone growth Effects 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 210000003205 muscle Anatomy 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 208000001076 sarcopenia Diseases 0.000 claims 3
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 206010019663 Hepatic failure Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 208000026072 Motor neurone disease Diseases 0.000 claims 2
- 206010028311 Muscle hypertrophy Diseases 0.000 claims 2
- 208000021642 Muscular disease Diseases 0.000 claims 2
- 201000009623 Myopathy Diseases 0.000 claims 2
- 201000002481 Myositis Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 230000005856 abnormality Effects 0.000 claims 2
- 230000009815 adipogenic differentiation Effects 0.000 claims 2
- 210000000577 adipose tissue Anatomy 0.000 claims 2
- 208000022531 anorexia Diseases 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 230000018678 bone mineralization Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000020411 cell activation Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 206010061428 decreased appetite Diseases 0.000 claims 2
- 230000018109 developmental process Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000002124 endocrine Effects 0.000 claims 2
- 238000001976 enzyme digestion Methods 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 201000006370 kidney failure Diseases 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 208000007903 liver failure Diseases 0.000 claims 2
- 231100000835 liver failure Toxicity 0.000 claims 2
- 210000002540 macrophage Anatomy 0.000 claims 2
- 230000002503 metabolic effect Effects 0.000 claims 2
- 208000005264 motor neuron disease Diseases 0.000 claims 2
- 230000037257 muscle growth Effects 0.000 claims 2
- 230000012042 muscle hypertrophy Effects 0.000 claims 2
- 201000006938 muscular dystrophy Diseases 0.000 claims 2
- 210000003098 myoblast Anatomy 0.000 claims 2
- 230000012107 myoblast migration Effects 0.000 claims 2
- 208000013315 neuromuscular junction disease Diseases 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 208000027232 peripheral nervous system disease Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 108091008146 restriction endonucleases Proteins 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 210000001057 smooth muscle myoblast Anatomy 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 241000283690 Bos taurus Species 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 241000282472 Canis lupus familiaris Species 0.000 claims 1
- 241000282994 Cervidae Species 0.000 claims 1
- 150000008574 D-amino acids Chemical class 0.000 claims 1
- 241000283086 Equidae Species 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims 1
- 102000007474 Multiprotein Complexes Human genes 0.000 claims 1
- 108010085220 Multiprotein Complexes Proteins 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 claims 1
- 238000012408 PCR amplification Methods 0.000 claims 1
- 241001494479 Pecora Species 0.000 claims 1
- 241000286209 Phasianidae Species 0.000 claims 1
- 241000700159 Rattus Species 0.000 claims 1
- 241000282887 Suidae Species 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000010367 cloning Methods 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 230000004807 localization Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 244000144977 poultry Species 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83552506P | 2006-08-03 | 2006-08-03 | |
| PCT/NZ2007/000203 WO2008016314A1 (en) | 2006-08-03 | 2007-08-02 | Myostatin antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013201653A Division JP5993827B2 (ja) | 2006-08-03 | 2013-09-27 | ミオスタチンアンタゴニスト |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009545313A JP2009545313A (ja) | 2009-12-24 |
| JP2009545313A5 true JP2009545313A5 (https=) | 2010-10-14 |
Family
ID=38997428
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009522733A Pending JP2009545313A (ja) | 2006-08-03 | 2007-08-02 | ミオスタチンアンタゴニスト |
| JP2013201653A Expired - Fee Related JP5993827B2 (ja) | 2006-08-03 | 2013-09-27 | ミオスタチンアンタゴニスト |
| JP2016074671A Withdrawn JP2016130251A (ja) | 2006-08-03 | 2016-04-01 | ミオスタチンアンタゴニスト |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013201653A Expired - Fee Related JP5993827B2 (ja) | 2006-08-03 | 2013-09-27 | ミオスタチンアンタゴニスト |
| JP2016074671A Withdrawn JP2016130251A (ja) | 2006-08-03 | 2016-04-01 | ミオスタチンアンタゴニスト |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8309068B2 (https=) |
| EP (1) | EP2054434B1 (https=) |
| JP (3) | JP2009545313A (https=) |
| CN (1) | CN101522707B (https=) |
| AU (1) | AU2007279456A1 (https=) |
| BR (1) | BRPI0715072A2 (https=) |
| CA (1) | CA2693378C (https=) |
| DK (1) | DK2054434T3 (https=) |
| WO (1) | WO2008016314A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1799709B1 (en) * | 2004-09-30 | 2012-04-04 | ORICO Limited | Myostatin isoform |
| PE20120532A1 (es) * | 2009-04-27 | 2012-05-18 | Novartis Ag | ANTICUERPOS ANTI-ActRIIB |
| CN101659700B (zh) * | 2009-07-27 | 2011-11-16 | 广州罗森生物科技有限公司 | 一种短肽 |
| NZ599604A (en) * | 2009-10-01 | 2014-07-25 | Myostin Therapeutics Pty Ltd | Synthetic myostatin peptide antagonists |
| JO3340B1 (ar) * | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| SG187867A1 (en) * | 2010-08-16 | 2013-03-28 | Amgen Inc | Antibodies that bind myostatin, compositions and methods |
| DK2780368T3 (en) | 2011-11-14 | 2018-02-05 | Regeneron Pharma | COMPOSITIONS AND PROCEDURES FOR INCREASING MUSCLE MASS AND MUSCLE STRENGTH BY SPECIFIC ANTAGONIZATION OF GDF8 AND / OR ACTIVIN A |
| EP3215175A4 (en) * | 2014-11-06 | 2018-06-27 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| KR20170135967A (ko) | 2015-04-15 | 2017-12-08 | 리제너론 파마슈티칼스 인코포레이티드 | Gdf8 억제제를 사용하여 강도 및 기능을 증가시키는 방법 |
| HRP20211081T1 (hr) | 2015-09-15 | 2021-10-15 | Scholar Rock, Inc. | Anti-pro/latentna miostatinska protutijela i njihove uporabe |
| CN115814077A (zh) | 2016-01-08 | 2023-03-21 | 供石公司 | 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法 |
| US11566047B2 (en) | 2016-08-10 | 2023-01-31 | Tokyo University Of Pharmacy & Life Sciences | Peptide or pharmaceutically acceptable salt thereof, or prodrug thereof |
| EP4218817A3 (en) * | 2017-01-06 | 2023-09-06 | Scholar Rock, Inc. | Methods for treating metabolic diseases by inhibiting myostatin activation |
| MX2020008991A (es) | 2018-03-01 | 2020-12-10 | Regeneron Pharma | Metodos para alterar la composicion corporal. |
| CN111902157B (zh) * | 2018-03-21 | 2023-08-04 | 松阳生技股份有限公司 | 促进局部肌肉增长、减缓或防止局部肌肉萎缩的组合物及其用途 |
| TWI649332B (zh) * | 2018-03-21 | 2019-02-01 | 英屬安圭拉商維多利亞生物醫學控股股份有限公司 | Composition for promoting local muscle growth, slowing or preventing local muscle atrophy and use thereof |
| JP7300764B2 (ja) * | 2018-07-02 | 2023-06-30 | キュラミス カンパニー・リミテッド | 細胞融合技術を用いた遺伝子及び細胞治療剤、並びにその用途 |
| US20220119489A1 (en) * | 2019-01-25 | 2022-04-21 | Children's Medical Center Corporation | Compositions and methods for treating muscular dystrophy and related disorders |
| WO2021060880A1 (ko) * | 2019-09-24 | 2021-04-01 | 마이오텍사이언스 주식회사 | 비천연 아미노산을 함유하는 근감소증의 예방 또는 치료용 약학적 조성물 |
| GB2636643B (en) * | 2020-12-03 | 2026-03-11 | Lart Bio Co Ltd | Transgenic animal having modified myostatin gene |
| EP4638496A1 (en) | 2022-12-22 | 2025-10-29 | Scholar Rock, Inc. | Selective and potent inhibitory antibodies of myostatin activation |
| CN120192396A (zh) * | 2023-12-21 | 2025-06-24 | 江苏省农业科学院 | 一种肌肉生长抑制素mstn蛋白突变体及其制备方法和应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4847325A (en) * | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
| US7393682B1 (en) | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
| US5874409A (en) | 1995-06-07 | 1999-02-23 | La Jolla Pharmaceutical Company | APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies |
| AU6274298A (en) | 1997-02-05 | 1998-08-25 | Johns Hopkins University School Of Medicine, The | Growth differentiation factor-8 |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| US6369201B1 (en) | 1998-02-19 | 2002-04-09 | Metamorphix International, Inc. | Myostatin multimers |
| TR200400621T2 (tr) | 1999-07-20 | 2004-08-23 | Pharmexa A/S | GDF-8 aktivitesinin aşağı doğru düzenlenmesi için bir yöntem. |
| US7368534B2 (en) | 2000-01-18 | 2008-05-06 | Orico Limited | Myostatin and mimetics thereof |
| WO2004011650A2 (en) | 2002-07-24 | 2004-02-05 | Intercell Ag | Antigens encoded by alternative reading frame from pathogenic viruses |
| MXPA05002968A (es) * | 2002-09-16 | 2005-09-08 | Univ Johns Hopkins | Activacion de miostatina por metaloproteasa, y metodos de modular la actividad de miostatina. |
| NZ529860A (en) | 2003-11-28 | 2006-10-27 | Ovita Ltd | Muscle growth regulator mighty and use in promoting muscle mass and treating muscle wasting diseases |
| EP1699820A2 (en) * | 2003-12-31 | 2006-09-13 | Schering-Plough Ltd. | Neutralizing epitope-based growth enhancing vaccine |
| AU2005272646A1 (en) * | 2004-08-12 | 2006-02-23 | Wyeth | Combination therapy for diabetes, obesity, and cardiovascular diseases using GDF-8 inhibitors |
| NZ538097A (en) * | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
| US20070190056A1 (en) | 2006-02-07 | 2007-08-16 | Ravi Kambadur | Muscle regeneration compositions and uses therefor |
-
2007
- 2007-08-02 CN CN2007800366228A patent/CN101522707B/zh not_active Expired - Fee Related
- 2007-08-02 EP EP07834817.4A patent/EP2054434B1/en not_active Not-in-force
- 2007-08-02 BR BRPI0715072-5A patent/BRPI0715072A2/pt not_active Application Discontinuation
- 2007-08-02 DK DK07834817.4T patent/DK2054434T3/en active
- 2007-08-02 CA CA2693378A patent/CA2693378C/en not_active Expired - Fee Related
- 2007-08-02 US US12/376,289 patent/US8309068B2/en not_active Expired - Fee Related
- 2007-08-02 AU AU2007279456A patent/AU2007279456A1/en not_active Abandoned
- 2007-08-02 JP JP2009522733A patent/JP2009545313A/ja active Pending
- 2007-08-02 WO PCT/NZ2007/000203 patent/WO2008016314A1/en not_active Ceased
-
2013
- 2013-09-27 JP JP2013201653A patent/JP5993827B2/ja not_active Expired - Fee Related
-
2016
- 2016-04-01 JP JP2016074671A patent/JP2016130251A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009545313A5 (https=) | ||
| US20200325200A1 (en) | Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) | |
| JP3859703B2 (ja) | ＴＧＦ−βファミリーの新規な成長／分化因子 | |
| TWI427084B (zh) | 穩定化之類胰島素生長因子多肽 | |
| EP1511507B1 (en) | Cell-permeable peptide inhibitors of the jnk signal transduction pathway | |
| JP2009515529A5 (https=) | ||
| JP7229284B2 (ja) | グルカゴン類似ペプチド－１受容体亢進剤を含む筋減少症治療用薬学組成物 | |
| JP2008500373A5 (https=) | ||
| JP2001512417A (ja) | Ｏｂ融合タンパク質組成物および方法 | |
| CN102741276A (zh) | 合成的肌肉抑制素肽拮抗剂 | |
| JP2009510999A (ja) | キメラ治療剤 | |
| KR20090118078A (ko) | 척수 손상 치료제 | |
| JP2023116739A (ja) | Ａｐｏｃ－ｉｉ模倣ペプチド | |
| US20220111017A1 (en) | Immunomodulatory compositions and methods | |
| EP3694537A1 (en) | Combination therapy for treatment of bone disorders | |
| JPH06508984A (ja) | ヒトのガラニン、ヒトのガラニンをエンコードするｃＤ ＮＡクローンとヒトのガラニン製造方法 | |
| CN1288754A (zh) | 提高饲料效率和家畜生长速度的基因处理 | |
| EP3010524B1 (en) | Protamine in treatment of neuronal injuries | |
| CN104379161A (zh) | 促进血管生长的蛋白质及其用途 | |
| JP2018095616A (ja) | アドレノメデュリン徐放性製剤 | |
| JP4520951B2 (ja) | インスリン分泌誘導剤及びインスリン分泌誘導組成物 | |
| JP6094485B2 (ja) | ビリルビン排泄促進剤 | |
| KR20180027924A (ko) | 글루카곤 유사 펩타이드-1(glp-1), glp-1 유래 펩타이드, 또는 glp-1 분해 억제제를 포함하는 근감소증 또는 근위축증 치료용 약학 조성물 | |
| JP2007238487A (ja) | 脊髄損傷に対する嗅粘膜移植にｈｇｆを用いた神経機能再建法 | |
| JP2025540675A (ja) | オクタデカニューロペプチド（ｏｄｎ）およびその合成誘導体を含む組成物、ならびに食物摂取、肥満、体重、吐き気および嘔吐の調節のための使用方法 |